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Ultra-fast stem cell labelling using cationised
magnetoferritin†
S. Correia Carreira,*‡a,b J. P. K. Armstrong,‡c A. M. Seddon,a,b A. W. Perriman,c
R. Hartley-Daviesd and W. Schwarzacher*b
Magnetic cell labelling with superparamagnetic iron oxide nanoparticles (SPIONs) facilitates many impor-
tant biotechnological applications, such as cell imaging and remote manipulation. However, to achieve
adequate cellular loading of SPIONs, long incubation times (24 hours and more) or laborious surface
functionalisation are often employed, which can adversely aﬀect cell function. Here, we demonstrate that
chemical cationisation of magnetoferritin produces a highly membrane-active nanoparticle that can mag-
netise human mesenchymal stem cells (hMSCs) using incubation times as short as one minute. Magneti-
sation persisted for several weeks in culture and provided signiﬁcant T2* contrast enhancement during
magnetic resonance imaging. Exposure to cationised magnetoferritin did not adversely aﬀect the mem-
brane integrity, proliferation and multi-lineage diﬀerentiation capacity of hMSCs, which provides the ﬁrst
detailed evidence for the biocompatibility of magnetoferritin. The combination of synthetic ease and
ﬂexibility, the rapidity of labelling and absence of cytotoxicity make this novel nanoparticle system an
easily accessible and versatile platform for a range of cell-based therapies in regenerative medicine.
Introduction
Cell labelling with magnetic nanoparticles has enabled a host
of platform biotechnologies for remotely manipulating, analys-
ing and visualising cells.1 Magnetic cell labelling typically
relies on endocytosis of superparamagnetic iron oxide nano-
particles (SPIONs), however, weak interactions between
SPIONs and the cell membrane make this a highly ineﬃcient
process.2,3 As a result, lengthy incubation times (24 hours and
more)4,5 and elevated SPION concentrations are required to
attain suﬃcient cell magnetisation. These conditions can
adversely aﬀect cell viability,6,7 moreover, cell types with low
internalisation capacity, such as lymphocytes, exhibit poor
SPION uptake even after 40 hours.8 There has been limited
success in enhancing cellular uptake by functionalising the
surface of SPIONs with antibodies,9,10 transfection agents,11,12
or cell-penetrating peptides,13,14 however, these approaches are
restricted by complex synthesis, expensive or cytotoxic
reagents,15 and problems such as nanoparticle aggregation
and precipitation.16 Accordingly, there is an unmet need for a
simple surface functionalisation methodology that can
produce a biocompatible SPION capable of rapidly magnetis-
ing a variety of cell types.
Here, we sought to develop a facile surface functionalisation
route to rapidly magnetise cells, thus avoiding lengthy
exposure times. Our approach includes the synthesis of a novel
cationised SPION derived from magnetoferritin, a protein-
based nanoparticle comprising a SPION core mineralised
inside the demineralised ferritin cavity.17 A major advantage of
magnetoferritin is the ease with which its magnetic properties
can be controlled, for instance by tuning the size of the
mineralised nanoparticle18,19 or by doping the core with
metals such as cobalt.20,21 Furthermore, the surrounding
protein shell aﬀords aqueous solubility and a large canvas of
addressable amino acids that can be chemically22–24 or geneti-
cally modified.25–27 We hypothesised that cationisation of
acidic amino acid residues on the magnetoferritin surface
would generate a magnetic bionanomaterial that would readily
interact with anionic domains present on the surface of a
variety of cell types (Scheme 1). In this study, we demonstrate
that cationised magnetoferritin can rapidly and persistently
magnetise stem cells using incubation times as short as one
minute without any adverse eﬀects on cell viability, self-
renewal and diﬀerentiation capacity. Our results represent a
†Electronic supplementary information (ESI) available: Detailed characterisation
data, and controls of the magnetisation and toxicological profiling studies. See
DOI: 10.1039/c5nr07144e
‡These authors contributed equally to this work.
aBristol Centre for Functional Nanomaterials, University of Bristol, Tyndall Avenue,
Bristol, BS8 1FD, UK. E-mail: S.Carreira@bristol.ac.uk
bH.H. Wills Physics Laboratory, University of Bristol, Tyndall Avenue, Bristol,
BS8 1TL, UK. E-mail: W.Schwarzacher@bristol.ac.uk
cSchool of Cellular and Molecular Medicine, University of Bristol, Medical Sciences
Building, University Walk, Bristol, BS8 1TD, UK
dBioengineering, Innovation, and Research Hub, University Hospitals Bristol NHS
Foundation Trust, St. Michael’s Hospital, Southwell Street, Bristol, BS2 8EG, UK
7474 | Nanoscale, 2016, 8, 7474–7483 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 1
8/
05
/2
01
6 
13
:2
1:
54
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View Issue
facile, rapid and versatile platform technology based on a non-
specific labelling mechanism applicable to a variety of cell
types. Furthermore, as it is possible to load the ferritin cavity
with alternative functional materials, such as radioisotopes,28
quantum dots29 or anti-cancer drugs,30 this technology pre-
sents new opportunities for a host of cationised ferritin-based
cell therapies.
Experimental section
Synthesis and cationisation of magnetoferritin
Cobalt-doped magnetoferritin was synthesised from commer-
cially available horse spleen apoferritin (ApoF) (Sigma Aldrich,
A3641, LOT 081M7011V) using an established protocol.17,31
Synthesis was performed in a double-jacketed reaction vessel
at 65 °C containing 75 mL of deoxygenated 50 mM HEPES-
NaOH (pH 8.6) with 3 mg mL−1 ApoF. The vessel was kept
under a nitrogen atmosphere to restrict oxidation of the metal
precursors. 30.3 mL of 25 mM ammonium iron sulfate hexa-
hydrate (Sigma Aldrich), containing 2.5% (w/v) cobalt sulfate
heptahydrate (Sigma Aldrich) was added at a rate of 0.15 mL
min−1. Controlled oxidation of the metal precursors inside the
apoferritin cavity was mediated by adding an equivalent
volume of an 8.33 mM hydrogen peroxide solution at the same
rate. Fresh metal precursor and hydrogen peroxide solutions
were injected three times at 65 minute intervals. The solution
was left to mature for 15 minutes prior to the addition of
1.5 mL of 1 M sodium citrate to chelate free metal ions in
the solution.
Large precipitates were removed by centrifuging the sample
for 30 minutes at 4350g and then passing the supernatant
through a 220 nm syringe filter. The protein was purified by
anion-exchange chromatography (ANX Sepharose 4 Fast Flow,
GE Healthcare, Life Sciences) to remove nanoparticles not
enclosed in the protein cavity, followed by size-exclusion
chromatography (HiPrep 26/60 Sephacryl S-300 HR column,
GE Healthcare, Life Sciences) to isolate protein monomers.
For cationisation, N,N-dimethyl-1,3-propanediamine
(DMPA, Sigma Aldrich) was coupled to aspartic and glutamic
acid residues on the MF surface using N-(3-dimethyl-
aminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC,
Sigma Aldrich) as described previously.24,32 Solutions of DMPA
were adjusted to pH 7 using HCl, before drop-wise addition of
MF or ApoF. After an equilibration period of three hours, the
coupling reaction was initiated by adding EDC and adjusting
the pH to 5 using HCl. The solution was continuously stirred
for four hours and then filtered through a 220 nm syringe
filter to remove any precipitates. The solution was extensively
dialysed (Medicell dialysis tubing, 12–14 kDa MWCO) against
50 mM phosphate buﬀer (pH 7) containing 50 mM NaCl to
yield stable solutions of cationised MF and cationised apoferri-
tin. Protein concentration was determined using a Bradford
assay (BioRad) using a calibration curve prepared from horse
spleen ferritin (Sigma Aldrich). In the Bradford assay, Coomas-
sie Brilliant Blue G-250 dye binds to aromatic and basic amino
acid residues on proteins, and the resulting complex results in
a shift in absorbance maximum from 465 nm to 595 nm. Inter-
ference of the assay with the iron core was evaluated by
measuring the absorbance spectrum of 1 mg mL−1 cat-MF
from 250 to 750 nm. The contribution of the iron core to the
absorbance at 595 nm (the wavelength at which the Bradford
assay is measured) was 7% of the total absorbance measured
at 595 nm after incubation with the Bradford reagent (Fig. S2
and S3†). Eﬀects of cationisation were evaluated by preparing
a range of concentrations of MF and cat-MF and determining
their absorbance using the Bradford assay. Absorbance values
and slopes of the linear fit were similar and variations between
MF and cat-MF were within error (Fig. S3†).
Characterisation of magnetoferritin (MF) and cationised
magnetoferritin (cat-MF)
Transmission electron microscopy (TEM) with a JEOL JEM
1200 EX was used to confirm mineralisation and determine
MF core size. Samples were observed both unstained or
stained with 2% (w/v) phosphotungstic acid (Sigma Aldrich).
Iron content in MF samples digested with 50% (v/v) nitric acid
was determined by inductively-coupled plasma optical emission
spectrometry (710 ICP-OES, Agilent). Zeta potential and
dynamic light scattering measurements of MF and cat-MF were
performed on a Malvern ZetaSizer Nano-ZS at a protein concen-
tration of approximately 1 mg mL−1 in 20 mM phosphate buﬀer
at pH 7. Matrix-assisted laser desorption ionisation time-of-
flight (MALDI-TOF) mass spectrometry was performed on ApoF
and cat-ApoF samples dissolved in an equivalent volume of
20 mg mL−1 of 2,5-dihydroxybenzoic acid in methanol.
Magnetic saturation and susceptibility of MF and cat-MF
were measured by performing a field sweep over ±2 Tesla at
300 K using a superconducting quantum interference device
(SQUID) magnetometer (Quantum Design). The diamagnetic
background of the sample tube (0.2 mL PCR tube, Corning)
and aqueous solvent were measured separately and subtracted
Scheme 1 Magnetoferritin synthesis, cationisation and magnetic cell
labelling (not to scale). (A) Apoferritin (1) is re-mineralised with iron and
cobalt salts to produce magnetoferritin (2). Carbodiimide-mediated
crosslinking of N,N’-dimethyl-1,3-propanediamine (DMPA) to surface
carboxyl groups yields cationised magnetoferritin (3). Solvent accessible
surface area representations show the distribution of acidic (red) and
basic (yellow) amino acid residues present on the protein surface. (B)
Rapid cell labelling is mediated by electrostatic interactions (dashed line)
between basic residues (4) present at the cationised protein surface and
anionic groups on proteoglycans, such as heparan sulfate residues (5)
within the glycocalyx of the cytoplasmic membrane.
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from the magnetic moment of the sample. Susceptibility was
calculated by determining the slope of the linear part of the
magnetisation curve. Molar T1 and T2 relaxivity was assessed
using a Siemens Magnetom Skyra 3 T MRI system. Samples
were serially diluted from 3 μM to 0.01 μM protein concen-
tration in Dulbecco’s Phosphate Buﬀered Saline (PBS, Sigma
Aldrich) and 200 μL of each solution was placed in tubes of a
PCR plate embedded in a 1.5% (w/v) carrageenan (Sigma
Aldrich) gel phantom. Longitudinal relaxation times (T1) were
determined using an inversion recovery spin echo sequence
(repetition time TR: 6000 ms, echo time TE: 9.6 ms, inversion
times TI: 50, 150, 250, 350, 450, 650, 850, 1250, and 2700 ms,
slice thickness: 3 mm, field of view: 12 cm). To measure trans-
verse relaxation times (T2), a spin-echo sequence with diﬀerent
echo times was used (TR: 3500 ms, TE: 10, 20, 30, 50, 80, 100,
160, 240, 480 ms, slice thickness: 3 mm, field of view: 12 cm).
T1 and T2 were determined by fitting an exponential curve to
the signal intensities at each inversion (TI) or echo time (TE),
respectively. Transverse and longitudinal relaxivity of each
sample was calculated using the T1 and T2 data along with the
MF iron content determined by ICP-OES.
Stem cell culture
Human mesenchymal stem cells (hMSC) were harvested from
the proximal femur bone marrow of osteoarthritic patients
undergoing total hip replacement surgery, in full accordance
with Bristol Southmead Hospital Research Ethics Committee
guidelines (reference #078/01) and after patient consent was
obtained. hMSCs were cultured at 37 °C and 5% CO2 atmo-
sphere in Dulbecco’s Modified Eagle’s Medium (DMEM),
1000 mg per L glucose (Sigma Aldrich), containing 10% (v/v)
foetal bovine serum (FBS, Sigma Aldrich), 1% (v/v) penicillin/
streptomycin (Sigma Aldrich), 1% (v/v) glutamax solution (Life
Technologies) and 5 ng mL−1 freshly supplemented human
fibroblast growth factor (PeproTech).
Magnetic stem cell labelling
For magnetic labelling, 150 000 hMSCs from three diﬀerent
patients were seeded into 25 cm2 tissue culture flasks and left
to adhere over night. Cells were washed with PBS and exposed
to 1 mL of MF or cat-MF in PBS for 1 minute to 6 hours with
concentrations ranging from 0.01–3 μM. After labelling, cells
were washed with PBS and harvested from the flasks using
trypsin/EDTA (Sigma Aldrich). Cell pellets were re-suspended
in 500 μL magnetic separation buﬀer (0.5% (w/v) FBS and
2 mM EDTA in PBS) and magnetic-activated cell separation
(MACS) was performed using MACS MS columns (Miltenyi
BIOTEC). Magnetic and non-magnetic fractions were collected
and the number of cells was determined using an Improved
Neubauer hemocytometer (Hawksley BS778). To assess
magnetisation eﬃciency, the fraction of magnetised cells was
determined using the following equation:
Magnetised cell fraction ¼ 100 nðMÞ=nðM þ NMÞ
n(M) is the number of cells in the magnetic fraction and
n(M + NM) is the sum of the number of cells in the magnetic
and non-magnetic fractions. Cells in the magnetic fractions
were digested with 50% (v/v) nitric acid before iron content
was determined using ICP-OES. The quantity of iron measured
was normalised to the number of cells in the analysed
fraction.
For the time course study, 150 000 cells were seeded into
75 cm2 tissue culture flasks and left to adhere over night. The
cells were washed with PBS and exposed to 1 mL of 0.5 μM cat-
MF for 30 minutes. The cat-MF supernatant was removed, the
cells washed with PBS and then cultured for up to five weeks.
Magnetisation and iron content of the cells were analysed at
weekly intervals using MACS and ICP-OES.
MRI imaging of labelled cells
800 000 hMSCs were seeded in 75 cm2 tissue culture flasks
and left to adhere over night. The cells were labelled with 3 mL
of 0.5 μM and 1 μM of MF or cat-MF for 30 minutes. The MF or
cat-MF supernatant was removed and cells were washed with
PBS, harvested with trypsin/EDTA and counted. 750 000
labelled cells were suspended in 200 μL of PBS and transferred
into tubes of a PCR plate embedded in a 1.5% (w/v) carragee-
nan gel phantom and left to settle by gravity for four hours
prior to MRI imaging. A gradient echo sequence was used with
TR = 100 ms, TE = 10 ms, and a flip angle of 30°.
To assess the long term retention of cat-MF 800 000 cells
were seeded into 75 cm2 flasks, left to adhere over night, and
then labelled with 3 mL of 0.5 μM of cat-MF for 30 minutes.
The cat-MF supernatant was removed, the cells were washed
with PBS, and cultured in DMEM for either four days or one
week before being harvested. 750 000 labelled hMSCs were sus-
pended in 200 μL of PBS and transferred into tubes of a PCR
plate embedded in a 1.5% (w/v) carrageenan gel phantom and
left to settle by gravity for four hours prior to MRI imaging
using a gradient echo sequence with TR = 100 ms, TE = 10 ms,
and a flip angle of 30°.
TEM imaging of labelled cells
50 000 hMSCs were seeded into a 6 well plate and left to
adhere over night. The cells were washed with PBS and
exposed to 1 mL of 0.5 μM cat-MF for 30 minutes. The cat-MF
supernatant was removed and the cells were washed with PBS.
Here, the cells were either immediately fixed and stained for
TEM imaging following established procedures33 or cultured
for one week before fixing and staining. Localisation of cat-MF
on labelled cells was investigated using a FEI Tecnai T12 trans-
mission electron microscope.
Prussian blue staining of labelled cells
1 000 000 hMSCs were seeded in culture medium into 75 cm2
tissue culture flasks and left to adhere overnight. The cells
were exposed to 3 mL of 0.5 μM of cat-MF for 30 minutes. The
cat-MF supernatant was removed, cells were washed with PBS
and left in culture medium for 24 hours. hMSCs were har-
vested with trypsin/EDTA and counted. 300 000 cells were sus-
pended in 30 μL of culture medium and loaded onto
fibronectin-coated polyglycolic acid (PGA) tissue engineering
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scaﬀolds of 5 mm diameter and 2 mm thickness (Biomedical
Structures, USA) and placed into the inner, agarose-coated
wells of a 24 well plate. Cells were left to adhere to the scaﬀold
over night, and then cultured for six hours in culture medium.
The medium was then removed and scaﬀolds fixed in 4% (w/v)
paraformaldehyde over night at room temperature, dehydrated
in 70% ethanol for two hours and then submitted to the Histo-
logy Services Unit (Medical Sciences, University of Bristol).
Histological sections of 10 μm thickness were immersed for
20 minutes at room temperature in a 10% (w/v) potassium
ferrocyanide solution (Sigma Aldrich, UK) containing an equal
volume of 2 M hydrochloric acid. Slides were washed in dH2O
three times for five minutes. Cell nuclei were counter stained
with a Nuclear Fast Red (Sigma Aldrich) for five minutes and
the excess stain was removed by rinsing with dH2O. Stained
sections were observed using an inverted light microscope at
40× magnification (Leica DM IRB).
Labelling mechanism of cat-MF
To assess the contribution of active internalisation processes
on cellular iron content 150 000 hMSCs were seeded into
25 cm2 tissue culture flasks and left to adhere over night.
hMSCs were exposed to 1 mL of 0.5 μM cat-MF for 5 or
30 minutes at 37 °C or 4 °C. Prior to incubation with cat-MF at
4 °C, cells were pre-cooled at 4 °C for 30 minutes in DMEM
supplemented with 20 mM HEPES buﬀer. After each incu-
bation period, the cat-MF supernatant was removed and the
cells were washed, harvested and analysed using ICP-OES.
To test the hypothesis that anionic proteoglycans in the
glycocalyx facilitate cat-MF uptake 150 000 cells were cultured
for four days in 25 cm2 tissue culture flasks using DMEM sup-
plemented with 80 mM sodium chlorate. hMSCs were labelled
with 1 mL of 0.5 μM cat-MF for 5 or 30 minutes at 37 °C before
the cat-MF supernatant was removed and the cells were
washed, harvested and analysed using ICP-OES.
The cellular iron content values after a 5 or 30 minute incu-
bation period were compared between groups labelled in
diﬀerent conditions using the Friedman test in IBM SPSS Stat-
istics version 21.
Cytotoxicity assays
For the MTS assay, 5000 cells from three diﬀerent patients
were seeded in quadruplicate into wells of a 96 well plate, left
to adhere over night, and exposed for 30 minutes to 125 μL of
MF or cat-MF at concentrations ranging from 0.01–3 μM, or
PBS only (untreated control). The supernatant was removed,
cells washed with PBS and cultured in DMEM. After 24 hours,
DMEM was removed, cells washed with PBS and incubated for
one hour at 37 °C with phenol-free DMEM containing 20% (v/v) of
MTS solution (CellTiter 96, Promega). Formation of the reduced
formazan product was measured at 490 nm using a spectro-
photometer (SpectraMax M5e, Molecular Devices). Cell viability
values were normalised with respect to the untreated control.
For the LDH assay (LDH Cytotoxicity Assay Kit, Pierce),
5000 cells from three diﬀerent patients were seeded in quadru-
plicate into wells of a 96 well plate, left to adhere over night
and exposed for 30 minutes to 125 μL of MF or cat-MF at con-
centrations ranging from 0.01 to 3 μM, PBS only (untreated
control), or a Lysis Buﬀer provided by the manufacturer as a
positive control. The supernatant was removed, cells washed
with PBS and cultured in DMEM with reduced serum content
(5% FBS) for 24 h after exposure to native MF or cat-MF,
because higher serum concentrations are known to interfere
with the assay. The assay was performed as per manufacturer’s
instructions using the cell culture supernatants. Percentage
(%) cytotoxicity was calculated using the following equation:
% cytotoxicity ¼ 100 ðLDHtreat  LDHUCÞ=ðLDHmax  LDHUCÞ
LDHtreat values were taken from cells treated with MF or cat-
MF. LDHUC was measured in the untreated cell control and
LDHmax was measured in cells treated with Lysis Buﬀer.
For statistical analysis of the MTS and LDH assays, data
were presented as mean ± standard deviation of three biologi-
cal repeats. Statistical analysis was performed using IBM SPSS
Statistics version 21. The means of groups treated with MF,
cat-MF, and PBS (untreated control) were compared using
Two-Way Analysis of Variance (ANOVA), in which eﬀects of
nanoparticle concentration as well as surface functionalisation
(un-functionalised vs. cationised) were investigated.
Cell proliferation assay
Proliferation of hMSCs was assessed using a cell counting
assay. 150 000 cells from three diﬀerent patients were seeded
into 75 cm2 tissue culture flasks and left to adhere over night.
hMSCs were exposed for 30 minutes to 3 mL of 0.5 μM cat-MF
or PBS (untreated cell control). The supernatant was removed,
cells washed with PBS and cultured in DMEM for up to three
weeks. At weekly intervals, cells were harvested, counted, and
population doublings were calculated as follows:
Population doublings ¼ logðn=150 000Þ=log 2
n was the number of counted cells, and 150 000 denotes the
number of cells initially seeded. Population doublings of the
cat-MF treated cells were normalised to the untreated cell
control. The population doubling values of cat-MF labelled and
untreated hMSCs were compared at each interval using the
Wilcoxon Signed-Rank test in IBM SPSS Statistics version 21.
Diﬀerentiation capacity of hMSCs after cat-MF labelling
The multi-lineage diﬀerentiation capacity of hMSCs was inves-
tigated using osteogenesis and adipogenesis in monolayer,
and chondrogenesis in a 3D cartilage engineering model. For
monolayer diﬀerentiation, 37 000 and 7400 hMSCs were
seeded into 24 well plates for adipogenesis and osteogenesis,
respectively, and left to adhere over night. Cells were exposed
to 0.75 mL of 1 μM of cat-MF or PBS (untreated control) for
30 minutes. The supernatant was removed, cells washed in
PBS and cultured in αMEM medium (Sigma Aldrich) with 10%
(v/v) FBS, 1% (v/v) penicillin/streptomycin and 1% (v/v) gluta-
max solution, containing either 50 μl mL−1 human osteogenic
supplement (StemXVivo, R&D Systems) or 10 μl mL−1 human
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2016 Nanoscale, 2016, 8, 7474–7483 | 7477
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 1
8/
05
/2
01
6 
13
:2
1:
54
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
adipogenic supplement (StemXVivo, R&D Systems) for three
weeks with media changes performed twice a week. Osteoblast
formation was visualised using Alizarin Red staining of
calcium phosphate deposits. Cells were washed with PBS and
fixed for one hour at 4 °C using 0.5 mL ice-cold 70% (v/v)
ethanol. The fixative was removed and the cells were incubated
with 0.5 mL alizarin red solution (Sigma Aldrich) for five
minutes at room temperature. The cells were then washed five
times with PBS.
Adipocyte formation was assessed using Oil Red staining of
intracellular lipid vacuoles. Cells were washed with PBS and
fixed with 4% (w/v) paraformaldehyde for 30 minutes at room
temperature. The fixative was removed and the cells washed
first with PBS followed by 60% (v/v) isopropanol. Cells were
incubated with 0.5 mL of Oil Red stain (Sigma Aldrich) for
30 minutes at room temperature. The stain was aspirated and
cells washed with 60% (v/v) isopropanol. Stained monolayers
were observed using an inverted light microscope at 10× mag-
nification (Leica DM IRB).
For tissue engineering of cartilage, 1 000 000 hMSCs were
seeded in 75 cm2 tissue culture flasks and left to adhere over
night. The cells were exposed to 3 mL of 0.5 μM of cat-MF or
PBS for 30 minutes. The cat-MF or PBS supernatant was
removed and cells were washed with PBS, harvested with
trypsin/EDTA and counted. 300 000 hMSCs were suspended in
30 μL of DMEM medium and loaded onto fibronectin-coated
PGA tissue engineering scaﬀolds of 5 mm diameter (Bio-
medical Structures, USA) and placed in the inner agarose-
coated wells of a 24 well plate. Cells were left to adhere to the
scaﬀold over night, and then cultured for one week in DMEM
containing 4500 mg glucose per L, 1% (v/v) penicillin/strepto-
mycin, 1% (v/v) glutamax, 1% (v/v) sodium pyruvate, and 1%
(v/v) insulin-transferrin-sodium selenite, supplemented with
100 nM dexamethasone, 80 nM ascorbic acid and 10 ng ml−1
TGFβ3. Three media changes were performed during this first
week, after which the medium was additionally supplemented
with 10 ng per ml insulin and scaﬀolds were cultured for a
further four weeks with media changes three times a week.
After five weeks in total, half of the scaﬀolds were stored at
−80 °C until biochemical analysis, and the other half was pre-
pared for histology. Histochemical staining of proteoglycans
was performed by incubating 5 μm sections of the tissue
engineered construct with a 5 mg mL−1 Safranin O solution
(Sigma Aldrich) for six minutes. Immunohistochemical stain-
ing was used to visualise type II collagen content. Goat Anti-
Type II Collagen (Cambridge Biosciences, UK, 1320-1) was the
primary antibody and Biotinylated Anti-Goat IgG (VECTASTAIN
Elite ABC Kit (Goat IgG), Vector Laboratories, UK, PK6105) was
the secondary antibody. Avidin and biotinylated horseradish
peroxidase macromolecular complex (VECTASTAIN Elite ABC
Kit) was used to bind to the secondary antibody and provide
an enzymatic base for the immunoperoxidase stain diamino-
benzidine tetrahydrochloride (ImmPACT DAB Substrate Kit,
Vectro Laboratories, UK), producing a brown stain. Sections
were also stained with Prussian Blue and Nuclear Fast Red to
assess the presence of cat-MF.
Biochemical analysis was performed to quantify the
amount of type II collagen and GAG in the engineered carti-
lage constructs. First, the constructs were weighed, and then
digested in a 2 mg mL−1 solution of TPCK-treated trypsin sup-
plemented with 200 mM iodoacetamide, 200 mM EDTA and
2 mg ml−1 pepstatin A (all Sigma Aldrich), first at 37 °C over
night, then for two hours at 65 °C. Samples were boiled for
15 minutes to inactivate trypsin and then centrifuged. The
supernatant containing the digested cartilage matrix com-
ponents was removed and the undigested scaﬀold freeze-dried
and weighed again. The dry weight of the extracellular matrix
was calculated by subtracting the dry weight of the undigested
scaﬀold from the dry weight of the whole cartilage construct.
Type II collagen was quantified by performing an enzyme-
linked immunosorbent assay (ELISA) developed by Hollander
et al.34 Briefly, samples along with calibration standards were
first incubated with a mouse-derived type II collagen antibody
(Bioiberica, Spain) over night, and then the supernatant was
transferred into plates coated with type II collagen and incu-
bated for 30 minutes at room temperature. The plate was then
washed and incubated with an anti-mouse secondary antibody
(Cambridge Biosciences, UK) for two hours at 37 °C. An alka-
line phosphatase solution was added to the plate and incu-
bated for 20 minutes at 37 °C before the absorbance was
measured at 405 nm. The amount of type II collagen was calcu-
lated from the calibration curve and expressed as a percentage
of the extracellular matrix dry weight.
Glycosaminoglycan (GAG) content was quantified using a
160 μg ml−1 dimethylmethylene blue solution, which was
added to samples and calibration standards of chondroitin
sulfate (Sigma Aldrich) and measured immediately at 530 nm.
The amount of GAG was calculated from the calibration curve
and expressed as a percentage of the extracellular matrix dry
weight.
The percentage of GAG or type II collagen in cat-MF treated
and untreated cartilage constructs was compared using the
Mann-Whitney U-test in IBM SPSS Statistics version 21.
Results and discussion
Synthesis and characterisation of cationised magnetoferritin
Cationised magnetoferritin (cat-MF) was prepared using a
facile two step synthesis (Scheme 1). First, cobalt-doped iron
oxide nanoparticles were mineralised within the apoferritin
cavity to produce magnetoferritin (MF), which was sub-
sequently cationised using carbodiimide coupling of N,N′-
dimethyl-1,3-propanediamine (DMPA) to acidic residues on
the protein surface (Fig. S1†). Transmission electron
microscopy (TEM) confirmed the presence of nanoparticles
within the protein cage (Fig. 1A), and image analysis of
unstained MF samples gave an average core diameter of 5.3 ±
1.1 nm (Fig. 1B and S4†). Using inductively-coupled plasma
optical emission spectrometry (ICP-OES), we measured an
average of 45 ± 8 μg of iron and 0.43 ± 0.17 μg of cobalt per
milligram of MF, indicating a 1% (w/w) cobalt doping of the
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iron oxide-based nanoparticle core. The nanoparticle size was
measured using dynamic light scattering, which gave a hydro-
dynamic diameter of 11.8 ± 1.1 nm for MF and 12.5 ± 1.4 nm
for cat-MF (Fig. S5A†), with the size increase attributed to the
steric bulk of coupled DMPA. Mass spectrometry revealed a
subunit molecular weight of 20.1 kDa for native apoferritin
and 21.1 kDa for cationised apoferritin (Fig. S5B†). This mass
increase corresponded to the cationisation of 288 residues on
the entire 24-subunit protein, which is consistent with pre-
vious cationisation eﬃciencies obtained using horse spleen
ferritin.32 Further evidence for cationisation was provided by
zeta potentiometry (Table 1), and time course cationisation
studies using ferritin showed that maximum zeta potential
was reached after two hours crosslinking time (Fig. S6†). Mag-
netic saturation, susceptibility and relaxivity were similar for
MF and cat-MF, indicating that cationisation had negligible
impact on the magnetic properties of the enclosed SPION
(Table 1, Fig. S7 and S8†). Although the relaxivity values of MF
and cat-MF were lower than those of commercially available
SPION-based contrast agents,35 higher iron loadings (and thus
relaxivity values) can be achieved by varying the mineralisation
protocol.18
Magnetic stem cell labelling with cationised magnetoferritin
Magnetic-activated cell separation (MACS) and ICP-OES
revealed that cat-MF was remarkably eﬀective at magnetically
labelling hMSCs (Fig. 2A). Notably, a one minute exposure to
0.5 μM cat-MF resulted in the magnetisation of 92% of the cell
population and the delivery of approximately 3.6 pg of iron, or
5 × 107 cat-MF nanoparticles, per cell. Remarkably, given the
extreme brevity of exposure, this cellular iron content is well
within the reported range required to influence T2 and T2*
contrast for MRI.36,37 Increasing the incubation time to six
hours resulted in saturation of cellular iron content at a level
of 20 pg iron per cell (Fig. S9†). The iron uptake rate between
1 and 30 minutes was 20.5 pg Fe per cell per hour, which
slowed significantly between 30 minutes and 6 hours to 1.2 pg
Fe per cell per h. A 30 minute incubation was used thereafter,
because this eﬀectively magnetised the entire cell population
and resulted in high cellular iron content within a reasonably
short time period. The cell magnetisation eﬃciency was also
dependent on incubation concentration, with more concen-
trated solutions of cat-MF magnetising a greater proportion of
hMSCs and resulting in a higher cellular iron content (Fig. 2B).
In contrast, all tested concentrations of un-functionalised MF
magnetised less than 3% of the cell population and cellular
iron content was below the ICP-OES detection limit (Fig. S10†).
These results demonstrate the direct impact of cationisation on
the eﬃciency of the magnetic labelling process.
Although other charge functionalisation strategies can
improve non-specific nanoparticle–cell interactions, cat-MF
labelling achieves greater labelling eﬃciency with lower incu-
bation concentrations. For instance, anionisation of SPIONs is
known to enhance cell labelling.38 However, this approach
required a 30 minute incubation with 5 mM iron to deliver
10 pg per cell, whereas cat-MF labelling attained the same cel-
lular iron loading with an incubation concentration of 0.2 mM
iron (this is the amount of iron contained in 0.5 μM cat-MF).
Cellular iron content after a one hour incubation with cat-MF
(15 pg) was also comparable to iron loadings achieved with
TAT-functionalised SPIONs (18 pg).39 Taken together, the
results presented in this work show for the first time that
eﬃcient magnetic labelling can be achieved within a one
minute incubation period, and that this eﬃciency can also be
achieved using relatively low extracellular iron concentrations.
Fig. 1 TEM analysis of MF. (A) Negative stain with 2% (w/v) phospho-
tungstic acid showing that the majority of protein shells (white) contain
a mineralised nanoparticle core (black). Scale bar: 50 nm. (B) Image ana-
lysis performed on an unstained TEM image of MF found a distribution
of core sizes with an average nanoparticle diameter of 5.2 ± 1.0 nm.
Error bars represent the Poisson counting error.
Table 1 Physicochemical characterisation of magnetoferritin (MF) and
cationised magnetoferritin (cat-MF)
MF cat-MF
Hydrodynamic diameter [nm] 11.8 ± 1.1 12.5 ± 1.4
Zeta potential [mV] −10.4 ± 0.2 8.3 ± 0.7
Magnetic saturation [emu g−1] 48.6 ± 1.8 47.5 ± 1.0
Magnetic susceptibility [×10−2 emu g−1 Oe−1] 1.3 ± 0.1 1.3 ± 0.1
Longitudinal relaxivity r1 [mM−1 s−1] 2.6 ± 0.1 2.3 ± 0.0
Transverse relaxivity r2 [mM−1 s−1] 44.6 ± 1.0 52.8 ± 0.8
Fig. 2 MACS and ICP-OES analysis of magnetised hMSCs. (A) Eﬀect of
labelling time on the percentage of magnetised cells and cellular iron
content in hMSCs exposed to 0.5 μM cat-MF. 92% of the cell population
was magnetised after just one minute, while the entire cell population
was magnetised in 15 minutes. Average and standard deviation of three
biological replicates are shown. (B) Eﬀect of cat-MF concentration on
magnetisation eﬃciency after a 30 minute incubation. Labelling
eﬃciency and cellular iron content were found to be concentration
dependent. Average and standard deviation of three biological replicates
are shown.
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Long-term studies using hMSCs labelled with 0.5 μM cat-MF
for 30 minutes revealed that 60% of the cell population
remained magnetised after one week in culture, and 10% after
five weeks. Cellular iron content decreased by approximately
60% per week (Fig. 3A), which is in agreement with the obser-
vation of a weekly population doubling in the magnetic cell
fraction (Fig. S11†). The cellular iron content dropped below
the detection limit of ICP-OES after four weeks in culture,
which is accompanied by a drop in the number of magnetised
cells. This reduction in iron content can be attributed to a
combination of dilution through transfer to daughter cells
during cell division,40 and lysosomal breakdown of the nano-
particles over time.41,42
MRI revealed a large T2* signal loss for hMSCs labelled
with cat-MF, compared to a control of unlabelled cells or cells
labelled with the equivalent concentration of un-functiona-
lised MF (Fig. 3B). In addition, the T2 relaxation rate increased
from 0.9 s−1 in unlabelled hMSC to 2 s−1 after cat-MF exposure
(Fig. S12A†). The contrast enhancement persisted for at least
one week, after which the T2 relaxation rate was 1.4 s−1
(Fig. S12B†). The r1 and r2 relaxivity values in cat-MF labelled
cells were 0.2 and 7.7 mM−1 s−1, respectively, and thus much
lower compared to the relaxivity values measured for free cat-
MF (Table 1 and Fig. S13†). A marked reduction in relaxivity
has previously been observed in SPIONs internalised by cells,
which was attributed to limited water and/or SPION diﬀusion
inside endocytotic vesicles.35,37 Taken together, these results
demonstrate that cat-MF labelling could be used to monitor
stem cell therapies over time using MRI.
TEM performed immediately after cell magnetisation
revealed widespread coverage of cat-MF across the cell surface
(Fig. 3C), however, no nanoparticles were detected at the cell
membrane after one week in culture (Fig. 3D). Given that the
majority of cells was still magnetised at this time point, it
follows that internalisation of cat-MF must have occurred. Evi-
dence for this hypothesis was provided by Prussian Blue stain-
ing, which revealed extensive iron deposits present within
sectioned hMSCs 48 hours after exposure to 0.5 μM cat-MF
(Fig. S14†).
The mechanism underlying rapid magnetic labelling with
cationised magnetoferritin
The incubation conditions were systematically varied to under-
stand the diﬀerent contributions of electrostatic interaction
and internalisation in cat-MF labelling (Fig. 4). Labelling at
37 °C and 4 °C for five minutes resulted in similar cellular
iron content, indicating that initial adsorption of cat-MF to the
cell surface was similar in both groups. However, after
30 minutes the iron content was significantly higher in cells
labelled at 37 °C compared to cells labelled at 4 °C. Low temp-
eratures are an eﬃcient method of non-invasively inhibiting
many active internalisation pathways.43 Therefore, these
results show that interactions between cat-MF and the cell
surface mediate rapid magnetic labelling during the first few
minutes of exposure, whilst active internalisation processes
contribute to increased cellular iron content during the later
stages of the labelling process. Furthermore, culturing hMSCs
in medium supplemented with 80 mM sodium chlorate
(NaClO3) significantly reduced the cellular iron content after a
five minute incubation with cat-MF (Fig. 4). NaClO3 inhibits
the synthesis of anionic functional groups on proteoglycans,44
which suggests that these glycocalyx species act as binding
sites for cat-MF during the initial labelling period, as has been
demonstrated for other cationic ligands.45 The observation
that NaClO3-treated cells still contained a relatively large
amount of iron suggests that other anionic moieties, such as
phospholipid head groups, may also contribute to electrostatic
Fig. 3 Long-term fate of cat-MF. (A) The percentage of magnetised
cells and cellular iron content of hMSCs labelled with cat-MF over ﬁve
weeks in culture. Average and standard deviation of three biological
replicates are shown. (B) MRI of 750 000 hMSCs labelled with MF and
cat-MF (3 T scanner, gradient echo, TR = 100 ms, TE = 10 ms, ﬂip angle
30°). Persistent contrast enhancement was observed in hMSCs labelled
with 0.5 μM cat-MF. (C) A TEM image of magnetised hMSCs immediately
after labelling with 0.5 mM cat-MF, revealing coverage of the cell
surface with nanoparticles. (D) A TEM image of magnetised hMSCs one
week after labelling, showing no nanoparticles at the cell surface. All
scale bars: 200 nm.
Fig. 4 Mechanistic study of cat-MF uptake. ICP-OES was used to
analyse the cellular iron content of hMSCs incubated with 0.5 μM cat-
MF for either 5 or 30 minutes at 37 °C, 4 °C, or 37 °C after NaClO3-treat-
ment. Average and standard deviation of three biological replicates are
shown. For each incubation period, cellular iron content values were
compared using the Friedman test, with signiﬁcant diﬀerences indicated
with an asterisk (p < 0.05).
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binding. After 30 minutes, the cellular iron content in cells
cultured in NaClO3 was still much reduced compared to cells
cultured in untreated medium. This indicates that initial
electrostatic adsorption of cat-MF to the cell surface is impor-
tant for high internalisation rates, which is in agreement with
previously calculated models that predict a higher rate of endo-
cytosis with increased ligand–receptor interactions.46 These
results are also consistent with models showing that non-
specific interactions are as important as specific interactions
during endocytosis, and even favour nanoparticle uptake.2
Toxicological evaluation of magnetoferritin and cationised
magnetoferritin
Although magnetoferritin has previously been explored as a
cellular contrast agent,18,47 no detailed toxicological evaluation
of this nanoparticle has been undertaken. Here, we investi-
gated acute eﬀects on cell viability and membrane integrity
using MTS and LDH assays performed 24 hours after exposure
to 0.01–3 μM solutions of MF or cat-MF. The MTS assay, which
uses cellular respiration as a measure of viability, showed no
significant eﬀects on cell viability after exposure to both MF
and cat-MF across this concentration range (Fig. 5A). This was
confirmed by an LDH assay, which showed that neither MF
nor cat-MF led to cytotoxic eﬀects aﬀecting cell membrane
integrity (Fig. 5B). The observation that similar viability levels
were measured for MF and cat-MF indicates that cationisation
did not confer additional cytotoxicity. This is a promising
result, because cationic nanoparticles are often more cytotoxic
than their anionic or neutral counterparts.48,49 This can be
attributed to the relatively low zeta potential of cat-MF, which
should avoid the hole formation observed in membranes
exposed to nanoparticles with excessively high cationic charge
density.50 The rapidity of cat-MF labelling also avoids the cyto-
toxic eﬀects associated with prolonged incubation time.6,7
Furthermore, the eﬃciency of cat-MF labelling allows the use
incubation concentrations several orders of magnitude lower
than many competing SPION systems.51 Finally, the biocompa-
tible protein shell of cat-MF circumvents the cytotoxic eﬀects
that can arise from coating agents used to synthesise functio-
nalised SPIONs.52
The long term eﬀect of magnetising hMSCs with cat-MF
was assessed using established proliferation and diﬀeren-
tiation assays. hMSCs incubated with 0.5 μM cat-MF prolifer-
ated to the same extent as untreated cells (Fig. S15†), while
monolayer diﬀerentiation into adipocytes and osteoblasts was
observed in hMSCs exposed to elevated concentrations (1 μM)
of cat-MF (Fig. 6A and B; see Fig. S16 and S17† for controls).
Furthermore, hMSCs labelled with 0.5 μM cat-MF were used to
grow cartilage constructs in a 35 day course of tissue engineer-
ing. Histochemical and immunohistochemical staining
revealed that proteoglycan and type II collagen production and
distribution was unaﬀected by cat-MF exposure (Fig. 6C and D;
see Fig. S17† for images of the untreated control). This was
confirmed by biochemical analysis of digested cartilage con-
structs, which showed that the level of glycosaminoglycan and
type II collagen was similar when magnetised and untreated
cells were used (Fig. S18†). Cartilage sections were also stained
with Prussian Blue to investigate whether cat-MF was still
present in the labelled cells after five weeks in culture. Blue
staining indicative of the presence of iron deposits was
observed in cartilage sections engineered from hMSC labelled
with cat-MF, but not in cartilage grown from untreated hMSCs
(Fig. S19†). Higher magnification imaging revealed that the
blue stain was co-localised with the cell matrix, indicating that
cat-MF was indeed still present within some cells. This is in
good agreement with the results reported above, which
showed that 10% of hMSCs still contained suﬃcient amounts
Fig. 5 Acute eﬀects of MF and cat-MF exposure in hMSCs. (A) Viability
and (B) cytotoxicity were assessed using an MTS and LDH assay, respect-
ively, 24 hours after exposure to MF and cat-MF for 30 minutes. Average
and standard deviation of three biological replicates are shown. All
values were normalised to an untreated hMSC control. No signiﬁcant
eﬀects of concentration or surface functionalisation on cell viability or
cytotoxicity were found using Two-Way Analysis of Variance. LB: lysis
buﬀer used to disrupt the cell membrane and release intracellular LDH
into the media (positive control).
Fig. 6 Diﬀerentiation capacity hMSCs after labelling with cat-MF.
Representative bright ﬁeld microscopy images of (A) hMSC-derived
osteoblasts with calcium phosphate deposits stained with Alizarin Red.
(B) hMSC-derived adipocytes with fatty vacuoles stained using Oil Red.
(C) Engineered cartilage tissue stained for proteoglycans with Safranin O
and (D) type II collagen using an immunohistochemical staining pro-
cedure. All scale bars: 100 μm.
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of cat-MF to be retained in a MACS column after five weeks in
culture.
Taken together, these results indicate that the two hall-
marks of viable stem cells, proliferation and diﬀerentiation,
were unaﬀected by exposure to cat-MF. The finding that cat-MF
labelling did not inhibit chondrogenesis is highly significant,
given that previous studies have shown that this diﬀerentiation
pathway can be adversely aﬀected by SPION exposure.53,54 For
example, Kostura et al. found that chondrogenesis was inhi-
bited after exposure to Feridex, which resulted in cellular iron
levels similar to ours (approximately 13 pg per cell).54
However, the exposure concentration and incubation time
used here were much lower compared to the study by Kostura
et al. Moreover, there is evidence that regulation of iron meta-
bolism is linked to chondrogenesis,55 which has been
suggested as the cause for the observed inhibition of this
diﬀerentiation pathway after SPION exposure. Here, labelling
with cat-MF introduced SPIONs encapsulated inside ferritin
shells. It is possible that internalised cat-MF may have been
able to withstand acidic environments of lysosomes better
because of the relatively acid-resilient protein cover compared
to the dextran coating of Feridex. Thus, iron ions might have
been released more slowly, avoiding sudden disruption of the
iron homeostasis.
Conclusions
We have demonstrated the synthesis of cationised magneto-
ferritin, a novel magnetic nanoparticle that rapidly and persist-
ently magnetises stem cells in just one minute, which is
several orders of magnitude shorter than most conventional
SPION systems. The magnetised hMSCs exhibited lasting MRI
contrast and retained capacity for self-renewal and diﬀeren-
tiation, which makes this novel SPION system an attractive
candidate for tracking stem cell therapy using MRI without
impairing the regenerative capacity of the labelled cells. Sig-
nificantly, chondrogenesis was not inhibited after cat-MF
exposure, which is a diﬀerentiation pathway that is often
aﬀected by SPION labelling. The facile nature of the cationisa-
tion procedure eliminates the need for laborious functionalisa-
tion chemistry, and the non-specific labelling mechanism
makes this a versatile technology that should find wide-spread
application in a range of diﬀerent cell types. Furthermore, the
apoferritin cage represents a highly flexible vector that can be
loaded with alternative functional molecules, thereby extend-
ing the presented concepts to applications beyond magnetic
labelling.
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